| scholarly article | Q13442814 |
| P2093 | author name string | Gastaut JA | |
| Blaise D | |||
| Maraninchi D | |||
| Stoppa AM | |||
| Boiron JM | |||
| Michallet M | |||
| Coso D | |||
| Damaj G | |||
| Faucher C | |||
| Mohty M | |||
| Bay JO | |||
| Tabrizi R | |||
| Bilger K | |||
| Michallet AS | |||
| Perreau V | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation | Q31828080 | ||
| Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma | Q33348936 | ||
| Estimation of failure probabilities in the presence of competing risks: new representations of old estimators | Q33594562 | ||
| High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma | Q34195428 | ||
| Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant | Q34753416 | ||
| The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review | Q35047863 | ||
| Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review | Q35071096 | ||
| Recent Developments in Hematopoietic Stem Cell Transplantation for Multiple Myeloma | Q35121623 | ||
| Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts | Q39244446 | ||
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects | Q40706569 | ||
| Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome | Q40752336 | ||
| Hematopoietic Cell Transplantation for Multiple Myeloma | Q40770162 | ||
| Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma | Q44071975 | ||
| Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality | Q44189564 | ||
| Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia | Q44237334 | ||
| Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen | Q44370136 | ||
| Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning | Q44418467 | ||
| Hematopoietic stem cell transplantation for hematological malignancies in Europe. | Q47908471 | ||
| Myeloma-reactive allospecific cytotoxic T lymphocytes lyse target cells via the granule exocytosis pathway. | Q52827001 | ||
| Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. | Q54028113 | ||
| Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. | Q54684597 | ||
| Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres | Q57904065 | ||
| Impact of complete remission with intensive therapy in patients with responsive multiple myeloma | Q57905040 | ||
| Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation | Q64038880 | ||
| Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia | Q68174936 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| High-dose sequential chemoradiotherapy, a widely applicable regimen, confers survival benefit to patients with high-risk multiple myeloma | Q72274191 | ||
| Autologous and allogeneic transplantation for multiple myeloma at a single centre | Q73304371 | ||
| Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM | Q73330861 | ||
| High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors | Q73356959 | ||
| Donor leukocyte infusions for multiple myeloma | Q73375198 | ||
| Distinct T-cell clonal expansion in the vicinity of tumor cells in plasmacytoma | Q73623079 | ||
| High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions | Q73784903 | ||
| Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant | Q73821836 | ||
| In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors | Q74613780 | ||
| Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma | Q74618779 | ||
| Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies | Q77093417 | ||
| Graft-versus-myeloma | Q77597294 | ||
| Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning | Q77706053 | ||
| Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study | Q78385763 | ||
| Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning | Q78834266 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 77-84 | |
| P577 | publication date | 2004-07-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation | |
| P478 | volume | 34 |
| Q27014801 | Advances in the autologous and allogeneic transplantation strategies for multiple myeloma |
| Q52699611 | Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma. |
| Q53148090 | Allo-SCT for multiple myeloma in the era of novel agents: a retrospective study on behalf of Swiss Blood SCT. |
| Q44984411 | Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome |
| Q38154518 | Allogeneic hematopoietic stem cell transplantation for multiple myeloma: what place, if any? |
| Q38162280 | Allogeneic transplantation in multiple myeloma |
| Q36194663 | Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma |
| Q44884259 | Chronic GVHD is associated with lower relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors |
| Q91884607 | Comparison of outcomes after human leukocyte antigen-matched and haploidentical hematopoietic stem-cell transplantation for multiple myeloma |
| Q36269952 | Current update on reduced intensity regimens for allogeneic stem cell transplantation |
| Q53310170 | EPOCH-F: a novel salvage regimen for multiple myeloma before reduced-intensity allogeneic hematopoietic SCT. |
| Q95762094 | Early lymphocyte recovery predicts longer survival after autologous peripheral blood stem cell transplantation in multiple myeloma |
| Q81798728 | Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT |
| Q37875193 | Guidelines for the diagnosis and management of multiple myeloma 2011. |
| Q37349835 | In pursuit of the allo-immune response in multiple myeloma: where do we go from here? |
| Q38064756 | In vivo T-cell depletion with antithymocyte globulins improves overall survival after myeloablative allogeneic stem cell transplantation in patients with hematologic disorders |
| Q34473121 | Is there still a role for allogeneic stem-cell transplantation in multiple myeloma? |
| Q46720756 | Long-term outcome of nonmyeloablative allogeneic transplantation in patients with high-risk multiple myeloma |
| Q36849339 | Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation |
| Q36481199 | Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience |
| Q36637651 | NY-ESO-1 immunotherapy for multiple myeloma |
| Q36031316 | Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the EBMT. |
| Q37424886 | Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis |
| Q33369092 | Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. |
| Q38488058 | Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation |
| Q80764931 | Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma |
| Q46508141 | Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group |
| Q84122228 | Role of allogeneic stem cell transplantation in multiple myeloma |
| Q42588915 | Role of allogeneic transplantation in multiple myeloma in the era of new drugs |
| Q45143154 | Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). |
| Q36902825 | The allogeneic dilemma |
| Q36556492 | The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma |
| Q83393625 | The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT |
| Q38677358 | The role of tandem stem cell transplantation for multiple myeloma patients |
| Q46270248 | Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial |
| Q37786502 | Unrelated stem cell transplantation for patients with multiple myeloma |
Search more.